Cerebral metabolic and behavioral effects of acutely administered nicotine were measured in rats in relation to dose. Nicotine 0.1, 1, or 10 mg/kg or vehicle was administered intraperitoneally to 3-month-old male Fischer-344 rats that had been pretreated with hexame thonium bromide 5 mg/kg i. p. to reduce peripheral auto nomic effects. Regional CMRglc (rCMRglc) values were measured, using the quantitative auto radiographic e4C]-2-deoxy-o-glucose method, in 71 brain regions, beginning 3 min after nicotine or vehicle administration. Intensity of body tremor, scored by a blinded rater, was dose related and peaked at 3 min after nicotine injection. rCMRglc rose in a dose-related manner: Nicotine 0.1 mg/kg had no sig nificant effect in any region, whereas 1 mg/kg elevated rCMR � lc significantly in 21 regions (mean rise 20%) and 10 mg/kg produced generalized (56 regions) and greater
Nicotine, an agonist of autonomic and neuromus cular acetylcholine receptors, has specific cholino mimetic effects on brain function (Stumpf and Gogolak, 1967) . In rats, low doses produce activa tion of the electroencephalogram and behavioral arousal. Progressively higher doses result in hip pocampal theta electrical activity, centrally medi ated tremor of trunk and limbs, and convulsions. Because these actions are not attenuated by mus carinic antagonists, nicotine is presumed to act at nonmuscarinic acetylcholine receptor sites in the brain. Two types of nicotine binding sites have been identified. The first is labeled preferentially by a-bungarotoxin (Morley et aI., 1977) , a specific an tagonist at cholinergic receptors of the neuromus-(mean rise 50%) increases in rCMRglc. Nicotine 1 mg/kg activated thalamic nuclei, cerebellum, geniculate nuclei, superior colliculus, median raphe, reticular formation, and the habenulointerpeduncular pathway, but was with out effect in the telencephalon. Effects of nicotine in the hindbrain were related anatomically to reported distribu tions of eHjnicotine and eH]acetylcholine but not e25I]u-bungarotoxin binding sites, implying that the former ligands label functional nicotine receptors. The pattern of change in rCMRglc after nicotine administration suggests that its cognitive effects in humans are due to augmented arousaUattention and visual processing rather than to direct neocortical or hippocampal activation. Key Words: Arecoline-Cerebral metabolism-Deoxyglu cose-Nicotine. cular junction. A second binding site is labeled pref erentially by eHlnicotine (Costa and Murphy, 1983) and by eHlacetylcholine in the presence of a mus carinic antagonist (Schwartz et aI., 1982) . Bound ligands at both sites are displaceable by unlabeled nicotine or acetylcholine. Recently, Clarke et al. (1985) showed that the regional binding patterns in rat brain of eHlnicotine and of e 25 I]a-bungarotoxin differ markedly. The pattern of eHlacetylcholine binding in the presence of a muscarinic antagonist in rat brain parallels that of eHlnicotine, suggesting that eH]nicotine preferentially labels the functional nicotine binding site (i.e., the nicotinic acetylcho line receptor). Increases in regional CMRglc (rCMRglc) have been found after nicotine administration to rats in two previous studies. In one (London et aI., 1985) , the effects in 12 brain regions of only a single dose were examined. In the other (Grunwald et aI., 1987) , dose-related rCMRglc effects of nicotine were reported, but the highest dose employed elevated rCMRgic in only 9 of 45 regions examined, and res-olution precluded measurements in some brain ar eas of particular interest. The present study was undertaken (a) to examine in greater detail the dose dependent effects of nicotine on regional brain me tabolism, (b) to determine whether the topography of metabolic alterations corresponds to the reported distribution of binding of eH]nicotine or e 2 5I]_ a-bungarotoxin, and (c) to compare the pattern of metabolic response to nicotine to that produced by muscarinic receptor stimulation (Soncrant et aI., 1985) . We measured rCMRglc in awake rats that re ceived one of three acute doses of nicotine. Be cause glucose is the major energy substrate for ner vous tissue, rCMRglc is an index of regional energy consumption, which is linked in turn to functional (neuronal) activity. In our laboratory, we have confirmed this relation after drug administration (Hodes et aI., 1985; Pizzolato et aI., 1985; Soncrant et aI., 1985) and have measured rCMRglc after the administration of several centrally acting drugs to explore the functional responsiveness of brain neu rotransmitter systems (Soncrant et aI., 1986 ). An abstract of this work has been published (McNa mara et aI., 1985) .
MATERIALS AND METHODS

Materials
Fischer-344 rats, 3 months of age, were obtained from Charles River (Wilmington, MA, U.S.A.). Animals had free access to food and water and were acclimated prior to use for at least 5 days to an environment in which temperature, humidity, and light cycle (on 0600-1800 h) were maintained. Nicotine hydrogen (+ )-tartrate was purchased from Gallard-Schlesinger (Carle Place, NY, U.S.A.). Hexamethonium bromide was obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.). [14C]_ 2-DeoxY-D-glucose (e4C]DG; 50-55 Ci/mol) in ethanol was purchased from New England Nuclear (Boston, MA, U.S.A.). The solution was evaporated and resuspended in isotonic saline. Thin layer chromatography was per formed on a cellulose plate (MN 300; Analtech, Newark, DE, U.S.A.) with isobutyric acid/ammonium hydroxide/ water, 66:1:33 (vol/voUvol), to establish its purity.
rCMRgIc
In a rat deprived of food for 18 h, anesthesia was in duced in a glass container with vaporized halothane and maintained for 15 min with 1% (vol/vol) halothane in ox ygen with a small animal respirator (Quantiflex; Fraser Harlake, Orchard Park, NY, U.S.A.) and a nose cone. Polyethylene catheters then were inserted into a femoral artery and vein, and the operative site was infiltrated with 1% lidocaine and closed with wound clips. The animal was placed in a loose-fitting plaster body cast in which the hindlimbs were restrained. This arrangement permitted free movement of head and forelimbs and had no effect on measured rCMRglc (Soncrant et aI., 1988) . Body temper ature was monitored and controlled via a rectal thermo probe connected to a thermostatic device (Indicating Controller 73ATA; Yellow Springs Instruments, Yellow Springs, OH, U.S.A.), which activated an external warm ing element when body temperature fell below 35.5°C. After a 4-h recovery period, [14C]DG 125 ILCilkg was ad ministered by rapid intravenous bolus infusion, and l00-1L1 timed arterial blood samples were removed 6, 18, 30, and 48 s and 1, 2, 3,5, 7.5, 10, 15,25,35 , and 45 min later. Samples were centrifuged immediately and plasma radioactivity (LS9000 Liquid Scintillation Spectrometer; Beckman Instruments, Irvine, CA, U.S.A.) and glucose (Glucose Analyzer II; Beckman) concentrations were measured.
The animal was killed 45 min after [14C]DG by an in travenous overdose of pentobarbital. The brain was re moved rapidly and frozen in methylbutane cooled to -40°C, then stored at -70°C. Coronal brain sections, 20 ILm thick, were prepared on a cryostat/microtome (Bright model 5030; Hacker Instruments, Fairfield, NJ, U.S.A.) at -20°C. Sections were mounted on coverslips and dried immediately at 55°C on a hot plate. Autoradio graphs then were prepared by exposing x-ray film for 7 days (SB-5; Eastman Kodak, Rochester, NY, U.S.A.) to the mounted sections, together with [14C]methyl methacrylate standards (Amersham, Arlington Heights, IL, U.S.A.).
Brain radioactivity was determined in 71 regions that were selected on the basis of the reported brain distribu tions of [3H]nicotine and [125l]a-bungarotoxin binding (Clarke et aI., 1985) , the effects of nicotine on neurotrans mitter release (Arqueros et aI., 1978; Andersson et aI., 1981; Bien and Herman, 1983 ), and regional rCMRglc ef fects of arecoline, a muscarinic cholinergic agonist (Son crant et al., 1985) . Using a semiautomated densitometer (Soncrant, 1986 ), a single experimenter obtained six sep arate optical density readings at each region in both left and right sides of the brain, and the means for the two sides were averaged. rCMRgl C was calculated from brain and plasma radioactivities and from plasma glucose con centrations, using equations and constants given by Sokoloff et al. (1977) .
Drug treatments
rCMRglc was assessed in five groups of six rats each. Four groups were pretreated with hexamethonium bro mide 5 mg/kg i.p. in distilled water (1 mUkg), 30 min be fore [14C]DG was injected. Hexamethonium, a nicotinic receptor antagonist that does not readily enter the brain (Gilman et aI., 1980) , was administered to reduce the pe ripheral effects of nicotine at autonomic and neuromus cular acetylcholine receptors. The remaining group re ceived an equal volume of distilled water. Each group then received an intraperitoneal injection of either dis tilled water (vehicle-vehicle and hexamethonium-vehicle control groups) or nicotine hydrogen tartrate 0.1, 1, or 10 mg/kg in distilled water (1 mUkg) at 3 min before the ad ministration of [14C]DG.
Behavior
Tremor was rated subjectively at fixed times after the second intraperitoneal injection, on the following scale: 0, no drug effect; I, hyperlocomotion and tremulousness; 2, tremor with occasional myoclonus; 3, marked tremor and myoclonus sufficient to impair locomotion; 4, convul sions. This was done by a single experimenter who was unaware of the prior drug treatment.
Physiological parameters
Mean arterial blood pressure and heart rate were as sessed before and at fixed times after the administration of nicotine or vehicle by connecting an arterial catheter to a pressure transducer (Statham Instruments, Hatorey, PR) that was attached to a paper chart recorder (model 2200; Gould, Cleveland, OH, U.S.A.). Baseline and sub sequent measurements of plasma glucose were made throughout the experiment (described above). The effect of nicotine on arterial blood gases was determined by comparing blood samples taken before the second intra peritoneal injection with samples just prior to death.
Statistical analysis
Using Dunnett's test (1974) for each physiological pa rameter, comparisons were made within each treatment group between baseline mean values (recorded before drug or vehicle administration) and values measured at 7 and 45 min after the second intraperitoneal injection (4 and 42 min after P4C]DG infusion). Arterial blood gas parameters (pH, P02, Pc02), measured at 45 min after t . he second intraperitoneal injection, were compared With baseline values by Student's t test. For each brain region, the rCMR I mean for the hexamethonium-treated control group wa� c compared with the remaining four groups' mean values, using analysis of variance and Dunnett's test. Statistical significance was taken as p < 0.05.
RESULTS
Physiological values
Vehicle or hexamethonium, administered to con trol animals, had no effect on measured physiolog ical parameters. Mean arterial blood pressure var ied by no more than 25% after various doses of nicotine and remained between 71 and 133 mm Hg. Nicotine 0. 1 mg/kg caused an initial 22% fall (p < 0.05) in mean blood pressure, whereas nicotine 10 mg/kg elevated mean blood pressure (p < 0.05) by 24%, with a compensatory 25% fall (p < 0.05) in heart rate. The plasma glucose concentration tended to rise during the course of the experiment in all groups, but always was <185 mg/dI. Fluctua tions in plasma glucose values are taken into ac count by the e4C]DG model and do not invalidate calculated values of rCMRglc (Sokoloff, 1982) . Body temperature was thermostatically controlled and did not vary statistically. Arterial blood pH, Po 2 , and Pco 2 were unchanged in all groups, except that a mild respiratory alkalosis was observed at 45 min in animals that received the highest dose of nicotine (10 mg/kg).
Behavior Tremor (Fig. 1 ) was seen in all animals that re ceived nicotine 10 mg/kg. It peaked in intensity at 3 min after nicotine injection and abated substantially by 8 min. Minimal tremor was observed in animals that received nicotine:;.:;: 1 mg/kg, and no tremor was seen in control rats. Each point represents the mean tremor score of six rats.
Marked tremor was observed in animals given nicotine 10 mg/kg; tremor peaked at 3 min, then declined. Minimal tremor occurred after smaller doses, and no tremor was ob served in control animals.
rCMRglc (Table 1) Values of rCMRglc in control animals were similar to those reported previously for awake young male rats (Sokoloff et aI., 1977; Pizzolato et aI., 1985; Soncrant et aI., 1985) . Hexamethonium alone had no significant effect on rCMRglc in any region. Com pared to hexamethonium, nicotine 0. 1 mg/kg pro duced no significant change in rCMRglc• After nic otine 1 mg/kg, rCMRglc was increased (p < 0.05) in 21 of the 71 brain regions studied, with a mean in crease for all regions equal to 20%. Nicotine 10 mg/kg increased rCMRglc (p < 0.05) in 56 of 71 re gions; the mean increase was 50%. rCMRglc did not decline significantly in any region after any dose of nicotine.
rCMRglc was increased in rats administered nic otine 1 mg/kg (compared to hexamethonium-treated controls; p < 0.05) in all thalamic nuclei studied (3 1-92%) and rose by 17-44% in three of four cer ebellar regions. Several primary sensory brain re gions, including the geniculate nuclei, superior col liculus, and medial terminal nucleus, were activated by nicotine 1 mg/kg. Dramatic increases in rCMRglc were observed in the habenulointerpeduncular pathway (medial habenula, + 58%; fasciculus ret roflexus, +6 1%; interpeduncular nucleus, +3 1%). rCMRglc was increased also after nicotine 1 mg/kg in the substantia nigra pars compacta, medial mamillary nucleus, reticular formation, median ra phe, and fornix.
DISCUSSION
The regional cerebral metabolic effects of nico tine 1 mg/kg in the present study are qualitatively similar to those reported after subcutaneous injec tion (London et aI., 1985) and continuous intrave nous infusion (Grunwald et aI., 1987) of nicotine in rats. Our results confirm and extend the finding of Grunwald et aI. (1987) that metabolic effects of nic otine are dose related; the highest dose, 10 mg/kg, altered rCMRglc in most regions examined, as do many drugs at high doses (Soncrant et aI., 1986) . Widespread effects of high drug doses likely are due to propagation of primary effects by neural circuitry and/or activation of compensatory neural mecha nisms (Pizzolato et aI., 1984; Soncrant et aI., 1985 Soncrant et aI., , 1986 . Additionally, tremor produced by nicotine 10 mg/kg may have activated somatosensory afferents. In contrast, a smaller and minimally tremorigenic dose of nicotine (1 mg/kg) elevated rCMRg1c in fewer regions, all of which were nontelencephalic structures. Selective metabolic activation of these regions presumably represents a specific action of nicotine, probably due in part to higher nicotine re ceptor densities (vide infra).
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Methodologic issues
Measurement of rCMRglc by the e4C]DG method may underestimate the peak effects of short-acting compounds like nicotine. This is because rCMRglc is measured over 45 min, the time during which [14C]DG is incorporated. Underestimation is mini mized, however, by a decrease over time in the amount of e4C]DG available for incorporation. Un der steady-state conditions, -50% of [14C]DG is in corporated in the first 10--15 min (Sokoloff et aI., 1977) , when nicotine's effects on behavior were most prominent ( Fig. O. Indeed, rCMRg1 C values reported in the present study are similar to those measured by Grunwald et aI. (1987) during contin uous intravenous nicotine infusion.
Dose-dependent increases in rCMRglc after drug administration are attributable to increased Na +,K + -ATPase activity, which is required to maintain transcellular ionic gradients following ac tivation of neurons (Mata et aI., 1980) . Because electrically induced increases in glucose utilization can be abolished by ouabain (Mata et aI., 1980) , an inhibitor of these enzymes and the sodium pump, it can be inferred that ion transport systems account in large part for increased glucose utilization under stimulatory conditions. For a given brain region, a drug-induced change in rCMRgic may be due to primary actions at active sites (e.g., receptors) located within the region or to secondary activation mediated by neural circuitry from other drug target areas. Many drugs alter rCMRglc in regions not known to possess receptors at which they act, and most agents, given in suf ficient doses, produce generalized changes in rCMRglc (see Soncrant et aI., 1986) . Low drug doses usually have more anatomically restricted cerebral metabolic effects that are likely to represent direct regional drug actions.
rCMRglc effects in relation to nicotine binding site distributions
In diencephalic and brainstem regions, there is appreciable concordance between rCMRglc eleva tions after nicotine 1 mg/kg ( Fig. 2a ) and the distri bution of [3H]nicotine binding sites reported by Clarke et ai. (1985) (Fig. 2b) . Conversely, the ob served rCMRglc effects of nicotine correlate poorly with the pattern of e 2 5I]u-bungarotoxin binding (Clarke et aI., 1985) (Fig. 2c ). For example, in the thalamus, which avidly binds eH]nicotine but not e 2 5I]u-bungarotoxin, rCMRglc was elevated by 31-92%. Other regions rich in eH]nicotine binding sites where metabolism was increased by nicotine 1 mg/kg are the medial habenula, dorsal lateral genic ulate nucleus, substantia nigra pars compacta, su perior colliculus, interpeduncular nucleus, and cer ebellum. Of regions possessing predominantly [1 2 5I]u-bungarotoxin sites, rCMRglc was increased in the ventral lateral geniculate and medial mamil lary nuclei, but not in the lateral mamillary nucleus, inferior colliculus, locus ceruleus, or hypothala mus. Because changes in rCMRglc after drug reflect altered regional functional (neuronal) activity (Son crant et aI., 1986), these findings indicate that eH]nicotine and not e 2 5I]u-bungarotoxin preferen tially labels functional receptors for nicotine in non telencephalic brain regions.
In forebrain structures, nicotine 1 mg/kg had no effect on rCMRglc, although the cerebral cortex and basal ganglia contain moderate to high numbers of eH]nicotine binding sites whose function is uncer tain. Nicotine evokes acetylcholine release from mouse and rat (Chiou et aI., 1970; Rowell and Winkler, 1984) cerebral cortical synaptosomes. In the CAl region of the rat hippocampus, nicotine reportedly has no effect on neuronal firing (Cole and Nicoll, 1984) , produces a small, short-lived in crease in population spikes (Ropert and Krnjevic, 1982) , or potently depresses electrical activity (Segal, 1978) . A combination of activation and in hibition by nicotine of electrical activity in different forebrain neuronal subpopulations presumably could have resulted in no net change in rCMRglc ' Alternatively, and more likely, the role of nicotine receptors in the telencephalon may be different from that of brainstem receptors.
Nicotine reportedly enhances performance on a variety of cognitive tasks, including tests of recall in humans (Mangan and Golding, 1983) and in rodents (Haroutunian et aI., 1985) . Its selective metabolic activation of lower brain structures in the rat, with sparing of neocortical and limbic areas, suggests that cognitive changes induced by nicotine may re sult from enhanced transmission in subcortical pathways mediating visual sensory input (superior colliculus, medial terminal nucleus, lateral genicu late) and/or attention and arousal (reticular forma tion), rather than by interaction with nicotine recep tors in the neocortex or hippocampus. Consistent with this interpretation is a recent report that nico tine, administered to humans with Alzheimer's dis ease, selectively improves performance on tests of attention and visual perception (Jones et aI., 1988) . Thus, despite the documented losses (Flynn and Mash, 1986; Nordberg and Winblad, 1986; White house et aI., 1986; Perry et aI., 1987) or changes in affinity (Nordberg et aI., 1988) of cortical and hip pocampal nicotinic receptors in Alzheimer's dis ease and their possible implication in memory def icits (Newhouse et aI., 1988; Whitehouse et aI., 1988) , the present results neither demonstrate a role for forebrain nicotine receptors in the cerebral re sponse to nicotine administration nor support its use to overcome neocortical receptor changes found in the disorder.
Effects of nicotine on rCMRglc in the habenulointerpeduncular pathway
Nicotine metabolically activated the medial ha benula, interpeduncular nucleus, and fasciculus ret roflexus (an interconnecting white matter tract). The specific function of the habenulointerpeduncu lar pathway is not fully understood, but it receives its major neuronal input from the septum (Suther land, 1982) and has thus been proposed to partici pate in limbic circuits. Many general anesthetics, barbiturates, and other hypnotics (Herkenham, 1981; Crosby et aI., 1982; McQueen et aI., 1984; Hodes et al., 1985) , while causing widespread re ductions in rCMRglc, spare or metabolically activate the habenulointerpeduncular pathway, apparently FIG. 2 . Schematic representations of regional brain metabolic effects of nicotine and arecoline and of regional distributions of nicotine binding site ligands. a: Regions in which regional CMRg,c (rCMRg,c) increased after nicotine 1 mg/kg (dark stippling) and 10 mg/kg (light and dark stippling). Nicotine 1 mg/kg selectively elevated rCMRg,c in thalamic and geniculate nuclei, reticular formation, cerebellum, the habenulointerpeduncular pathway, and a few other regions, but was without effect in neocortex or hippocampus. band c: Reported distributions of binding sites for [3Hjnicotine and [125Ija-bungarotoxin, respectively (after Clarke et aI., 1985) . Note that nicotine-rather than bungarotoxin-Iabeled binding sites correspond with selective metabolic effects of nicotine (a). d: Brain regions in which rCMRgic was elevated by arecoline, a muscarinic cholinergic agonist (after Soncrant et aI., 1985) . Arecoline 0.5 mg/kg elevated rCMR gi c (dark stippling) selectively in the reticular formation, hippocampus, and amygdala, whereas 5 mg/kg (light and dark stippling) produced generalized increases. A, amygdala; ACC, accumbens n.; AUD, auditory cortex; c, substantia nigra pars compacta; Cn, cerebellar deep nuclei; CP, caudate/putamen; dR, dorsal raphe n.; FR, frontal cortex; GI, lateral geniculate n.; GP, globus pallid us; HB, habenula (medial and lateral); HEMI, cerebellar hemisphere (gray matter); HIP, hippocampus; HTH, hypothalamus; IC, inferior colliculus; lPN, interpeduncular n.; LC, locus ceruleus; MED, medial cortex; mG, medial geniculate n.; MM, mamillary n.; MOT, motor cortex; mR, median raphe n.; mV, medial vestibular n.; R, red n.; RF, reticular formation; S, medial septum; SC, superior colliculus; SNr, substantia nigra pars reticulata; SS, somato sensory cortex; STH, subthalamic n.; TH, thalamus; VIS, visual cortex.
in relation to the dose administered (Hodes et al., 1985) . Although the mechanism and consequences of this phenomenon are not known, it is interesting that nicotine pretreatment prolongs the period of unconsciousness produced by pentobarbital in ro dents Alderete, 1983, 1986) . As a con sequence of elevated local blood flow coupled to augmented metabolism, nicotine could increase the delivery and, hence, concentrations of barbiturate in regions of the habenulointerpeduncular pathway. However, this mechanism is unlikely, as lipophilic J Cereb Blood Flow Metab, Vol. 10, No. 1, 1990 compounds can diffuse laterally in brain to rapidly achieve uniform regional drug concentrations (Jay et al., 1988) . Moreover, anesthetic-induced activa tion of the habenulointer p eduncular pathway prob ably is not due to a direct effect on the pathway itself, but rather to actions elsewhere, as the acti vation can be abolished by prior lesions of afferents to the medial habenula from the septum (Herken ham, 198 1). More likely, nicotine prolongs pento barbital-induced unconsciousness by fu rther acti vating the habenulointerpeduncular tract through a facilitatory or independent mechanism, perhaps mediated by nicotinic receptors found in high den sity in the medial habenula and interpeduncular nu cleus (Clarke et aI., 1985; Hamill et aI., 1986) .
Comparison of rCMRglc effects of nicotine and arecoline
Both nicotine and arecoline (Soncrant et aI., 1985) , a muscarinic cholinergic agonist, increase rCMRglc in the reticular formation, perhaps ac counting for the widespread use of these drugs by humans (in tobacco and betel nuts, respectively) as stimulants. Otherwise, however, nicotine's regional effects on glucose utilization were strikingly differ ent from those observed after muscarinic stimula tion with arecoline, although both cause elevations of rCMRglc in many regions. We have reported that arecoline increases rCMRglc in a dose-related man ner in young Fischer-344 rats (Soncrant et aI., 1985) . After arecoline 0.5 mg/kg i.p., rCMRglc is selectively increased in the hippocampus and amygdala (in addition to the mesencephalic reticu lar formation) among 95 regions studied (Fig. 2d ). Nicotine 1 mg/kg, on the other hand, preferentially elevated rCMRglc in some diencephalic, brainstem, and cerebellar regions but was without effect in lim bic structures. This dichotomous regional metabolic response to muscarinic and nicotinic stimulation in dicates that neuronal responses to physiologic ace tylcholine release are preferentially mediated, on a regional basis, by either muscarinic or nicotinic re ceptors. These results predict that attempts to re store deficient muscarinic neurotransmission in Alzheimer's disease by pharmacologically increas ing synaptic acetylcholine (e.g., with anticholines terases or release-enhancing drugs) may function ally activate several other brain regions by nicotine receptor stimulation.
